JP2019514343A5 - - Google Patents

Download PDF

Info

Publication number
JP2019514343A5
JP2019514343A5 JP2018542268A JP2018542268A JP2019514343A5 JP 2019514343 A5 JP2019514343 A5 JP 2019514343A5 JP 2018542268 A JP2018542268 A JP 2018542268A JP 2018542268 A JP2018542268 A JP 2018542268A JP 2019514343 A5 JP2019514343 A5 JP 2019514343A5
Authority
JP
Japan
Prior art keywords
domain
seq
polypeptide
fragment
staphylococcal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018542268A
Other languages
English (en)
Japanese (ja)
Other versions
JP7117244B2 (ja
JP2019514343A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2017/050763 external-priority patent/WO2017137954A2/en
Publication of JP2019514343A publication Critical patent/JP2019514343A/ja
Publication of JP2019514343A5 publication Critical patent/JP2019514343A5/ja
Application granted granted Critical
Publication of JP7117244B2 publication Critical patent/JP7117244B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018542268A 2016-02-12 2017-02-10 黄色ブドウ球菌疾患の間にコアグラーゼ活性を中和する抗体に関連した組成物および方法 Expired - Fee Related JP7117244B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662294413P 2016-02-12 2016-02-12
US62/294,413 2016-02-12
PCT/IB2017/050763 WO2017137954A2 (en) 2016-02-12 2017-02-10 Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease

Publications (3)

Publication Number Publication Date
JP2019514343A JP2019514343A (ja) 2019-06-06
JP2019514343A5 true JP2019514343A5 (enExample) 2020-03-26
JP7117244B2 JP7117244B2 (ja) 2022-08-12

Family

ID=59563610

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018542268A Expired - Fee Related JP7117244B2 (ja) 2016-02-12 2017-02-10 黄色ブドウ球菌疾患の間にコアグラーゼ活性を中和する抗体に関連した組成物および方法

Country Status (5)

Country Link
US (2) US11214600B2 (enExample)
EP (1) EP3416979A4 (enExample)
JP (1) JP7117244B2 (enExample)
AU (1) AU2017218768B2 (enExample)
WO (1) WO2017137954A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9181329B2 (en) * 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
HRP20201127T1 (hr) * 2012-04-26 2020-11-27 University Of Chicago Antigeni stafilokokne koagulaze i metode primjene istih
AU2020273471B2 (en) 2019-05-14 2026-05-07 The University Of Chicago Methods and compositions comprising Staphylococcus protein A (SpA) variants
US12528882B2 (en) 2019-09-13 2026-01-20 The University Of Chicago Methods and compositions for treating staphylococcal infections
CN114062665B (zh) * 2020-08-05 2023-04-28 菲鹏生物股份有限公司 示踪粒子标记目标分子及其制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610293B1 (en) 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
WO2000012132A1 (en) 1998-08-31 2000-03-09 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
DE69940371D1 (de) 1998-09-14 2009-03-19 Nabi Biopharmaceuticals Rockvi Beta-glucan enthaltende zusammenstellungen und spezifische immunoglobuline
EP2298340B1 (en) * 2004-09-22 2014-04-16 GlaxoSmithKline Biologicals S.A. Immunogenic composition for use in vaccination against staphylococcei
MY148405A (en) * 2006-03-30 2013-04-30 Glaxosmithkline Biolog Sa Immunogenic composition
AR060187A1 (es) * 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Composicion inmunogenica
GB0700136D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
EP3281947B1 (en) 2009-04-03 2020-02-12 The University of Chicago Compositions and methods related to protein a (spa) variants
NZ612315A (en) * 2009-04-14 2014-10-31 Novartis Ag Compositions for immunising against staphylococcus aureus
ES2655701T3 (es) * 2010-07-02 2018-02-21 The University Of Chicago Composiciones y métodos relacionados con variantes de la proteína A (SpA)
WO2012136653A1 (en) * 2011-04-08 2012-10-11 Novvac Aps Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus
NZ702282A (en) 2012-04-26 2016-07-29 Univ Chicago Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease
HRP20201127T1 (hr) 2012-04-26 2020-11-27 University Of Chicago Antigeni stafilokokne koagulaze i metode primjene istih
WO2015057893A2 (en) * 2013-10-15 2015-04-23 The Texas A&M University System Compositions and the use of a fibrinogn binding motif presence in efb and coa for vaccine against staphylococcus aureus and drug delivery
WO2015112895A2 (en) * 2014-01-24 2015-07-30 Church William R Antibody specific to staphylococcus aureus, therapeutic method and detection method using same

Similar Documents

Publication Publication Date Title
JP6317670B2 (ja) ブドウ球菌プロテインａに対する抗体に関連した組成物および方法
RU2770209C2 (ru) Терапевтические антитела против лиганда cd40
JP2014525933A5 (enExample)
JP6251730B2 (ja) 黄色ブドウ球菌（ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）疾患の間にコアグラーゼ活性を中和する抗体に関連した組成物および方法
JP2016529882A5 (enExample)
AU2008294038A1 (en) Antigen-binding proteins targeting S. aureus ORF0657n
CN111732654B (zh) 一种抗SARS-CoV-2的单克隆抗体1E10
AU2016334290B2 (en) Antibody to hepatitis B surface antigen and use thereof
JP2018514193A5 (enExample)
KR102058381B1 (ko) 인간 ｌ１ｃａｍ에 대한 인간화 항체 및 그의 제조 방법
EP3288974B1 (en) Type iii secretion system targeting molecules
EP3496750A2 (en) Combination therapy
WO2020029860A1 (zh) 针对狂犬病病毒的双特异性抗体及其用途
AU2019267050B2 (en) Epitope of regulatory T cell surface antigen and antibody specifically binding thereto
JP2021508495A5 (enExample)
WO2025242094A1 (zh) 靶向bdca2的抗体或其抗原结合片段及其应用
CN116715757A (zh) 全人源抗狂犬病毒中和抗体及其用途
JP6556758B2 (ja) 黄色ブドウ球菌特異的抗体、それを用いた治療方法及び検出方法
JP2024506020A5 (enExample)
JP2023550628A5 (enExample)
RU2015129655A (ru) Антитело человека, специфичное к матапневмовирусу человека, или антиген-связывающий фрагмент указанного антитела
JP2019511457A5 (enExample)
WO2019128119A1 (zh) 一种针对破伤风毒素的全人源单克隆中和抗体及其应用
EP4536704A2 (en) Igf1r antibodies
US20240059764A1 (en) ANTIGEN-BINDING PROTEIN TARGETING STAPHYLOCOCCUS AUREUS a-HEMOLYSIS AND APPLICATION THEREOF